All
Cancer 'grid' allows sharing of information
August 1st 2005Anaheim, Calif. — The cancer Biomedical Informatics Grid, or caBIG, is an important introduction of information technology to the war on cancer, much the same as information technology has been used to transform business and the military, according to Kenneth H. Buetow, Ph.D., director of the NCI Center for Bioinformatics and laboratory chief, Laboratory of Population Genetics, National Cancer Institute, Bethesda, Md.
Systemic sunscreen still in future, despite promise of antioxidants
August 1st 2005Vienna, Austria — Although there appears to be potential for developing systemic methods of protecting skin from sun damage, researchers still seem to be a long way from determining how to do that, according to Harald Maier, M.D.
Tumor, oxygen link provides clues for new cancer therapies
August 1st 2005Philadelphia — The unraveling of the relationship between tumor growth and falling oxygen levels is expanding what is known about cancer and encouraging research into new antitumor therapies, according to M. Celeste Simon, Ph.D.
Today's fillers: Carefully consider product choices for patients to achieve 'customized' outcomes
August 1st 2005The broad range of fillers available today allows dermatologists to target any depth of the skin and treat an array of cosmetic defects. Now, according to Kevin Pinski, M.D., the emphasis is on indications, and analyzing the skin of each patient to determine which fillers would be best and then tailoring a treatment plan that's just right for that person.
Pseudolymphoma presents as leonine facies
August 1st 2005Newport Beach, Calif. — A rare instance of cutaneous pseudolymphoma presenting as leonine facies was recently diagnosed in Southern California and treated successfully with a prolonged prednisone taper, says Rebecca Scudiero, M.D., a resident in the division of dermatology, David Geffen School of Medicine, UCLA.
Doctor's system measures severity of psoriasis for practice, clinical trials
August 1st 2005Ann Arbor, Mich. — Accurate, reliable and appropriate documentation of the severity of psoriasis is important in clinical practice and essential for clinical trial research, says Charles N. Ellis, M.D., professor and associate chair, department of dermatology, University of Michigan Medical School.
Novel technology affords safe, efficient iontophoretic transdermal drug delivery
August 1st 2005New Orleans — Transdermal delivery of hyaluronic acid is possible using a technology combining microdermabrasion with a novel electrophoretic system (Ultrapeel with Transderm Ionto, Mattioli Engineering), and this procedure appears to be a safe and effective method for improving facial rhytids, says Jaggi Rao, M.D.
Specialty hospitals can expect federal scrutiny
August 1st 2005Washington — Physicians seeking to open specialty hospitals that focus on specific practices or procedures can expect to face careful scrutiny from federal regulators who believe those facilities may be generating windfall profits for doctors while creating unfair competition for traditional hospitals and ambulatory surgery centers (ASCs).
New vaccine said to reduce risk of shingles
July 5th 2005National report -- Findings of a study reported recently in the New England Journal of Medicine indicate that a one-time shot of a vaccine developed by Merck & Co. significantly reduces adults' chances of acquiring shingles, a painful, sometimes debilitating nerve and skin condition.
Oracea phase 3 clinical trials show 'highly significant' results
July 1st 2005Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.
Clindamycin-tretinoin combo effective for acne
July 1st 2005National Report - Pooled results from two phase 3 clinical trials demonstrate the efficacy and safety of an investigational acne treatment combining clindamycin and tretinoin in a hydrogel base (Velac, Connetics), James J. Leyden, M.D., reported at the 63rd Annual Meeting of the American Academy of Dermatology.
Psoriasis: Treatment combinations require blend of art, science
July 1st 2005Dallas - Most patients with moderate to severe psoriasis are best treated with a combination of topical, phototherapy and/or systemic agents that can be used in a variety of sequences, says Alan Menter, M.D., chairman, division of dermatology, Baylor University Medical Center.
Nonablative light-based therapy evolving
July 1st 2005Las Vegas - Nonablative light-based therapy continues to evolve, and with recent innovations, that field has advanced into the use of combination therapies for better outcomes and the ability to simultaneously address both cosmetic and medical skin problems, said Mark S. Nestor, M.D., Ph.D., at the Fall & Winter Dermatology Conference here.
Economics focus of topical acne treatment comparison
July 1st 2005National report — Among topical medications for treating mild-to-moderate acne, antibiotics are the most cost-effective therapy for inflammatory acne while retinoids are the most cost-effective for clearing non-inflammatory lesions, according to the results of a pharmacoeconomic evaluation reported by Stefan Weiss, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology.